Table 3.

Univariate and multivariate analysis of response to CARTr for peripheral BCR

No. of participants = 40	Univariate analysis			Multivariate analysis
	OR	95% CI	P value	OR	95% CI	P value
Prior HSCT (n = 15)	1.859	0.50-6.94	.356	5.175	0.83-32.31	.079
BCR ≤3 mo after CARTi (n = 22)	0.898	0.25-3.25	.870	0.996	0.20-4.90	.996
CART product
Investigational CTL019 (n = 17)	REF			REF
HuCART19 (n = 14)	2.400	0.55-10.53	.246	1.313	0.12-14.28	.823
Commercial tisagenlecleucel (n = 9)	1.200	0.21-6.80	.837	0.344	0.04-3.00	.334
Previously treated with a different CART product (n = 7)	1.313	0.25-6.88	.748	0.444	0.04-5.10	.513
Lymphodepletion prior to CARTr (n = 28)	11.000	1.25-97.02	.031	33.570	2.07-543.24	.013

REF, reference.